Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia.

Qian J, Lin J, Qian W, Ma JC, Qian SX, Li Y, Yang J, Li JY, Wang CZ, Chai HY, Chen XX, Deng ZQ.

Leuk Res. 2013 Jul;37(7):765-8. doi: 10.1016/j.leukres.2013.03.014. Epub 2013 Apr 11.

PMID:
23582927
2.

Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia.

Chen XX, Lin J, Qian J, Qian W, Yang J, Ma JC, Deng ZQ, Xie D, An C, Tang CY, Qian Z.

Clin Biochem. 2014 Jan;47(1-2):63-6. doi: 10.1016/j.clinbiochem.2013.09.020. Epub 2013 Oct 14.

PMID:
24135052
3.

Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.

Li Y, Lin J, Yang J, Qian J, Qian W, Yao DM, Deng ZQ, Liu Q, Chen XX, Xie D, An C, Tang CY.

Leuk Res. 2013 Dec;37(12):1642-7. doi: 10.1016/j.leukres.2013.09.022. Epub 2013 Sep 30.

PMID:
24138945
4.

MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status.

Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F.

J Hematol Oncol. 2012 Jun 8;5:26. doi: 10.1186/1756-8722-5-26.

5.

Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.

Rücker FG, Russ AC, Cocciardi S, Kett H, Schlenk RF, Botzenhardt U, Langer C, Krauter J, Fröhling S, Schlegelberger B, Ganser A, Lichter P, Zenz T, Döhner H, Döhner K, Bullinger L.

Leukemia. 2013 Feb;27(2):353-61. doi: 10.1038/leu.2012.208. Epub 2012 Jul 19.

PMID:
22810507
6.

Prognostic value of miR-96 in patients with acute myeloid leukemia.

Zhao J, Lu Q, Zhu J, Fu J, Chen YX.

Diagn Pathol. 2014 Mar 29;9:76. doi: 10.1186/1746-1596-9-76.

7.

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M.

J Clin Oncol. 2011 Jul 20;29(21):2889-96. doi: 10.1200/JCO.2011.35.4894. Epub 2011 Jun 13.

PMID:
21670448
8.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
9.

The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.

Sun SM, Rockova V, Bullinger L, Dijkstra MK, Döhner H, Löwenberg B, Jongen-Lavrencic M.

Leukemia. 2013 Jan;27(1):100-6. doi: 10.1038/leu.2012.158. Epub 2012 Jun 13.

PMID:
22692398
10.

Increased expression of miR-24 is associated with acute myeloid leukemia with t(8;21).

Yin JY, Tang Q, Qian W, Qian J, Lin J, Wen XM, Zhou JD, Zhang YY, Zhu XW, Deng ZQ.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):8032-8. eCollection 2014.

11.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
12.

High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.

Zhang TJ, Lin J, Zhou JD, Li XX, Zhang W, Guo H, Xu ZJ, Yan Y, Ma JC, Qian J.

Gene. 2018 Jan 15;640:79-85. doi: 10.1016/j.gene.2017.10.034. Epub 2017 Oct 12.

PMID:
29032147
13.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
14.

Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia.

Zhang TJ, Wang YX, Yang DQ, Yao DM, Yang L, Zhou JD, Deng ZQ, Wen XM, Guo H, Ma JC, Lin J, Qian J.

Clin Lab. 2016;62(1-2):113-20.

PMID:
27012040
15.

Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.

Liu L, Chen R, Zhang Y, Fan W, Xiao F, Yan X.

Diagn Pathol. 2015 Jul 17;10:109. doi: 10.1186/s13000-015-0345-6.

16.

Prognostic value of miR-29a expression in pediatric acute myeloid leukemia.

Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z.

Clin Biochem. 2013 Jan;46(1-2):49-53. doi: 10.1016/j.clinbiochem.2012.09.002. Epub 2012 Sep 12.

PMID:
22981932
17.

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).

Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K.

Blood. 2013 Jun 6;121(23):4769-77. doi: 10.1182/blood-2012-10-461624. Epub 2013 Apr 30.

18.

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 Feb 1;28(4):578-85. doi: 10.1200/JCO.2009.23.0342. Epub 2009 Dec 28.

PMID:
20038731
19.

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.

Ovcharenko D, Stölzel F, Poitz D, Fierro F, Schaich M, Neubauer A, Kelnar K, Davison T, Müller-Tidow C, Thiede C, Bornhäuser M, Ehninger G, Brown D, Illmer T.

Exp Hematol. 2011 Oct;39(10):1030-1042.e7. doi: 10.1016/j.exphem.2011.07.008. Epub 2011 Jul 22.

PMID:
21784052
20.

Differential expression of specific microRNA and their targets in acute myeloid leukemia.

Cammarata G, Augugliaro L, Salemi D, Agueli C, La Rosa M, Dagnino L, Civiletto G, Messana F, Marfia A, Bica MG, Cascio L, Floridia PM, Mineo AM, Russo M, Fabbiano F, Santoro A.

Am J Hematol. 2010 May;85(5):331-9. doi: 10.1002/ajh.21667.

Supplemental Content

Support Center